Italian campaign to abolish red tape and help glaucoma patients

Article

Dr Tiziana Fattori of Per Vedere Fatti Vedere onlus in Italy explains the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma.

Dr Tiziana Fattori of Per Vedere Fatti Vedere onlus in Italy explains the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma.

“Between 2004/5 a specific procedure for patients to obtain a National Health Service reimbursement for medicines used in glaucoma treatment was established in Italy. This procedure is called Nota 78 and is subject to the control of AIFA, the Italian agency for pharmaceutical products.

“Under the current procedure once a year, but in some regions even twice or three times a year, every patient suffering from glaucoma has to submit their therapeutic plan, drafted and signed by a MD Ophthalmologist, listing all the medicines used for treating glaucoma. This document must be draft in three copies: one copy needs to be handled to his/her NHS doctor, one copy sent to the NHS and one copy kept in a file. Only if you undertake this cumbersome procedure can you obtain the NHS reimbursement for your glaucoma treatment. The therapeutic plan is always the same, given the chronic nature of the disease and therefore it does not make any sense to repeat the procedure on a regular basis, producing an enormous paperwork and waste of time both for patients, doctors and NHS.

“Alarmingly, a recent research undertaken in Emilia Romagna has shown that, since this procedure is in place, an increasing percentage of glaucoma patients are not taking up any treatment for glaucoma, most likely due to having to cope with this bureaucratic and absurd procedure, typical of some ancient inheritance of our country.

“So, on World Glaucoma Day Per Vedere Fatti Vedere onlus is inviting Italian glaucoma patients, their families, NHS doctors and ophthalmologists to send a message of protest- by fax or email- to AIFA and the Ministry of Health asking the abolition of this oppressive burden currently imposed on glaucoma patients. Whoever wants to participate in our campaign can visit our website www.pervederefattivedere.it download the message of protest and fax/email details and send their message.”. A strong media coverage is also planned to support this campaign.

Tiziana Fattori can be contacted at Tel: +39 06 44361575Contact fattori@pervederefattivedere.it

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.